Financial Performance Summary

Quarterly Results (Q2 FY2026):

  • Sales: ₹376 crores, up 18% year-over-year (YoY)
  • Profit After Tax (PAT): ₹112 crores, up 26% year-over-year (YoY)

Performance Drivers

The sales growth of 18% was driven by:

  • Strong brand fundamentals
  • Superior retail execution
  • Positive consumer response to new innovations
  • Strengthened go-to-market capabilities

The PAT growth of 26% was led by:

  • Growth in sales
  • Productivity improvements across the value chain

Management Commentary

Milind Thatte, Managing Director, P&G Health India, stated that the company delivered another strong quarter with double-digit topline and bottom-line growth, continuing the momentum of previous quarters. The growth reflects:

  • Positive response from consumers, patients, and healthcare professionals (HCPs) to science-backed superior healthcare products and innovations
  • Growing consumer focus on preventive health
  • Impact of strong retail execution, new consumer communication, and HCP awareness initiatives
  • Strengthened go-to-market and supply chain capabilities

Strategic Framework

The company's strategy is centered on:

  • Focused portfolio of quality, trusted, and highly recommended brands
  • Superiority across product, package, brand communication, retail execution, and value
  • Constructive disruption
  • Productivity improvements
  • Agile accountable organization

Company Background

Procter & Gamble Health Limited is one of India's largest vitamins, minerals, and supplements (VMS) companies manufacturing and marketing VMS products including:

  • Neurobion
  • Livogen
  • SevenSeas
  • Evion
  • Polybion
  • Nasivion

The company focuses on products for a healthy lifestyle and improved quality of life.

Contacts

  • Media Contact: Vishesh Bohre (bohre.v@pg.com)
  • Agency Contact: Malika Bhavnani (malika.bhavnani@madisonpr.in)